BC Innovations | Aug 30, 2019
Translation in Brief

DNA trumps protein in Huntington onset

Two independent studies from former Teva CSO Michael Hayden and a Boston-based consortium suggest long, uninterrupted stretches of DNA repeats -- not the amino acids they encode -- could be the key to predicting and...
BC Innovations | Oct 4, 2018
Distillery Therapeutics


INDICATION: Anemia Cell culture and mouse studies suggest inhibiting SH2B3 could help treat FANCD2-deficient Fanconi anemia, a disorder involving loss of hematopoietic stem and progenitor cells (HSPCs). In FANCD2-deficient mouse HSPCs, SH2B3 knockout increased growth...
BC Innovations | Jun 11, 2009
Distillery Therapeutics

Indication: Hematology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Anemia Fanconi anemia complementation group A (FANCA); FANCD2 Studies in human cells suggest that induced pluripotent stem (iPS) cells carrying wild-type...
BC Week In Review | Jan 5, 2009
Clinical News

Biomarker Panels diagnostic data

Data from 115 evaluable patients with triple negative breast cancers enrolled in a U.S. trial showed that a panel of 4 DNA repair proteins (XPF, FANCD2 , MLH1 and MK2 ) met the primary endpoint of predicting...
Items per page:
1 - 4 of 4